J. Wang - Bristol Myers Squibb, Princeton, NJ USA

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

POSB387 Leveraging Real-World Data for Time-to-Event Endpoints in Clinical Trials

D Parashar, P Almgren, A Berglund, A Guasconi,C Smith, B Torlinska,J Wang, Q Wang

Value in Health（2022）

引用0浏览0引用

P963: evolution of treatment patterns and overall survival in patients with relapsed/refractory multiple myeloma receiving a second line of therapy between 2012 and 2020: analysis of the preamble cohort

D. Kuter, H. Goldschmidt,D. Cella, M. T. Petrucci, P. Moreau, B. Durie, A. Juarez-Garcia, L. Trong, J. Gu, G. Hernandez Rivera, S. Dhanasiri, T. Marshall,

HemaSphere（2022）

引用0浏览0引用

Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis

H. Einsele,J. Berdeja,N. S. Raje,D. S. Siegel,Y. Lin,L. D. Anderson,P. Rodriguez-Otero,S. Manier,M. Cavo,A. Truppel-Hartmann,E. Rowe, J. Sanford,

BLOOD（2021）

引用18浏览0引用

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of high-risk patient (Pt) subgroups in the KarMMa study

H. Goldschmidt,N. S. Raje,D. Siegel,S. Jagannath,S. Lonial,N. C. Munshi,P. Moreau,M. Cavo, A. Truppel-Hartmann,E. Rowe,L. Huang,A. Agarwal,

ONCOLOGY RESEARCH AND TREATMENT（2021）

引用0浏览0引用

KarMMa study: Characterization of Cytokine Release Syndrome (CRS) in patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with Idecabtagene Vicleucel (ide-cel, bb2121)

H. Einsele,A. Kansagra,Y. Lin,J. Berdeja,N. Shah,A. Oriol,I Yakoub-Agha,A. Rambaldi, A. Truppel-Hartmann,E. Rowe,J. Wang,A. Agarwal,

ONCOLOGY RESEARCH AND TREATMENT（2021）

引用0浏览0引用

Single-Dose Pharmacokinetics Of Bms-986177/Jnj-70033093 In Participants With Mild Or Moderate Hepatic Impairment Compared To Healthy Participants

V Perera, G Abelian,D Li,Z Wang, L Zhang, S Lubin,J Wang,A Bello,B Murthy

EUROPEAN HEART JOURNAL（2020）

引用5浏览0引用

First-In-Human Study To Assess The Safety, Pharmacokinetics And Pharmacodynamics Of Bms-986177/Jnj-70033093, A Direct, Reversible, Small Molecule Factor Xia Inhibitor In Healthy Volunteers

V Perera,Z Wang, J Luettgen,J Wang,D Li, M Desouza, M Cerra, D Seiffert

EUROPEAN HEART JOURNAL（2020）

引用2浏览0引用

Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial

K. Weisel, H. Einsele, H. Goldschmidt,M. Delforge,J. San Miguel,K. B. Bertin,M. Tahir, H. Lewis,J. Wang,J. Braverman, T. B. Campbell,N. Munshi

ONCOLOGY RESEARCH AND TREATMENT（2020）

引用0浏览0引用

Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects: a randomized 3-period crossover study

Y Song,Z Wang,I Perlstein,J Wang, F LaCreta,R J A Frost,C Frost

JOURNAL OF THROMBOSIS AND HAEMOSTASIS（2017）

引用35浏览0WOS引用

EXPLORATORY EXPOSURE-SAFETY ANALYSES OF INX-08032 IN SUBJECTS WITH HEPATITIS C VIRUS INFECTION RECEIVING BMS-986094 (INX-08189)

P. H. Chan, M. AbuTarif,T. Eley,B. He,P. Yin, P. Sukumar, H. Kandoussi,J. Wang, R. Bertz

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2015): S45-S46

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn